Slide 1Current & Future Perspectives in the Treatment of Heart Failure Slide 2 Stewart et al. Eur J of Heart Failure 2001, 3(3):pp315-322. HF – More malignant than…

Slide 1Cost-Effectiveness of Left Ventricular Assist Devices (LVADs) as Permanent Implants for End-Stage Heart Failure David Samson Blue Cross and Blue Shield Association…

Slide 1Single Center Experience On Different Anticoagulation Protocols In The Management Of Veno-Arterial ECMO C. Amarelli Department of Cardiovascular Surgery and Transplants…

Slide 1Secrets of The Heart Between Science and Belief ABDUL DAEM AL KAHEEL www.kaheel7.com/eng Translated by: Ahmed Adham [email protected] Slide 2 Have they not…

Folie 1 Results of the Longest and Largest Ever -Blockade Study in CHF Mortality Reduction beyond ß 1 -Blockade Pub.: Results: Poole-Wilson et al. Lancet 2003;362:7-13 Design:…

1.Myocarditis ECM, 2/7/142. Clinical presentation Acute myocarditis presentation: highly variable, rangingfrom subclinical disease to fulminant heart failure Of 3055…

1.Myocarditis ECM, 2/7/142. Clinical presentation Acute myocarditis presentation: highly variable, rangingfrom subclinical disease to fulminant heart failure Of 3055…

1. INTRODUCTIONA Ventricular Assist Device (VAD) is a mechanical circulatory device that isused to partially or completely replace the pumping action of a failing human heart.Unlike…

Treating Cardiovascular disease in patients with cancer presents a unique challenge for the clinician The mechanisms might differ from the usual pathogenesis, and thus extrapolating…

Treating Cardiovascular disease in patients with cancer presents a unique challenge for the clinician The mechanisms might differ from the usual pathogenesis, and thus extrapolating…